The right choice of treatment regimen as the key to successful therapy of wet AMD Original research study

Main Article Content

Agnieszka Lisiak
Wojciech Suda
Jarosław Kocięcki

Abstract

Age-related macular degeneration remains the main cause of central vision impairment in the elderly population in developed countries. Currently, the most effective method that significantly inhibits the progression of wet AMD is intravitreal anti-VEGF injections. Not only the selection of the right active substance, but also the schedule of their administration plays an important role in proper therapy. The AMD Drug Program has significantly increased the availability of modern treatment for Polish patients. However, possible therapeutic plans still do not include the so-called treat-and-extend scheme. In our work we showed the significant advantages of the above scheme over currently available in the Polish Drug Program.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Lisiak A, Suda W, Kocięcki J. The right choice of treatment regimen as the key to successful therapy of wet AMD. Ophthatherapy [Internet]. 2020Dec.17 [cited 2024Mar.29];7(4):295-01. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/1117
Section
Conservative treatment

References

1. Bowling B. Kanski Okulistyka kliniczna. Izdebska J, Szaflik J (ed). Edra Urban & Partner, Wrocław 2013.
2. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984; 102(11): 1640-2.
3. Epstein D, Amren U. Near vision outcome in patients with age-related macular degeneration treated with aflibercept. Retina 2016; 36(9): 1773-7.
4. Eleftheriadou M, Vazquez-Alfageme C, Citu CM et al. Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am J Ophthalol. 2017; 174: 160-8.
5. Kaiser P, Singer M, Tolentino M et al. Long-term safety and visual outcome of intravitreal aflibercept in neovascular age-related macular degeneration; VIEW 1 Extension Study. Ophtalmol Retina. 2017; 1(4): 304-13.
6. Holtz FG, Tadayoni R, Beatty S et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015; 99(2): 220-6.
7. Chin-Yee D, Eck T, Fowler S et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment for neovascular age-related macular degeneration. Br J Ophthalmol. 2016; 100(7): 914-7.
8. Okada M, Kandasamy R, Chong EW et al. The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis. Am J Ophthalmol. 2018; 192: 184-97.
9. Barthelmes D, Nguyen V, Daien V et al. Two year outcomes of ‘treat and extend’ intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. Retina 2018; 38(1): 20-8.
10. Traine P, Pfister IB, Zandi S et al. Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a ‘treat-and-extend’ regimen. Ophthalmol Retina. 2019; 3(5): 393-9.
11. https://www.gov.pl/web/zdrowie/choroby-nieonkologiczne.
12. Jaffe GK, Kaiser PK, Thompson D et al. Differential response to anti-VEGF regiments in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology. 2016; 123(9): 1856-64.
13. Schmidt-Erfurth U, Chong V, Loewenstein A et al. Guidelines for the management of the neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014; 98(9): 1144-67.
14. Mekjavić PJ, Gregorcic B, Oberc C et al. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia. BMC Ophthalmol. 2018; 18(1): 333.
15. Wykoff CC, Ou WC, Brown DM et al. Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-year Results of the TREX-AMD Study. Ophthalmol Retina. 2017; 1(4): 314-21.